Financial News

Consolidated revenue increased by 1.1% to EUR 305.8 million as compared to the prior-year period (Q1 2025: EUR 302.4 million). This was again driven primarily by the "Branded pharmaceuticals" segment, which generated a sharp increase in revenue of 11.7%. This more than offset the slight decline in revenue in the "Other healthcare products" segment and the budgeted decrease in revenue in the "Parallel import business" segment.

Grünwald, 31 March 2026 – Dermapharm Holding SE ("Dermapharm"), an innovative and rapidly growing manufacturer of branded pharmaceuticals and other healthcare products, today published its full Annual Report and Sustainability Report for the 2025 financial year and confirmed the previously published preliminary consolidated figures (IFRS).

Grünwald, Germany, 10 March 2026 – The Management Board of Dermapharm Holding SE (the "Company") (ISIN DE000A2GS5D8 / WKN A2GS5D) resolved today, with the approval of the Supervisory Board of the Company and on the basis of the authorization granted by the Annual General Meeting of the Company on 14 June 2023, to make a public share buyback offer to the shareholders of Dermapharm Holding SE for a total of up to 4,300,000 shares (representing approximately 7.99% of the share capital of the Company) at an offer price of EUR 42.00 per share. The repurchased shares are intended to be cancelled.

Grünwald, 10 March 2026 – Dermapharm Holding SE ("Dermapharm"), an innovative and rapidly growing manufacturer of branded pharmaceuticals and other healthcare products, today published its unaudited preliminary consolidated figures (IFRS) for the 2025 financial year.

Grünwald, 13 November 2025 – Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals and other healthcare products, today publishes its results for the first nine months of 2025.

Grünwald, 26 August 2025 – Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals and other healthcare products, today published its report (reviewed by the auditor) for the first half of the current 2025 financial year and confirmed the preliminary consolidated figures (IFRS).

Grünwald, 15 May 2025 – Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals and other healthcare products, today publishes its results for the first three months of 2025.

Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals and other healthcare products, today published its full Annual Report for the 2024 financial year and confirmed the previously published preliminary consolidated figures (IFRS).

Dermapharm Holding SE ("Dermapharm"), an innovative and rapidly growing manufacturer of branded pharmaceuticals and other healthcare products, today published its unaudited preliminary consolidated figures (IFRS) for 2024 financial year.

Dermapharm Holding SE posts strong results for Q3 2024, Arkopharma (France) back above prior-year EBITDA levels for first time

Grünwald, 27 August 2024 – Dermapharm Holding SE ("Dermapharm"), an innovative and rapidly growing manufacturer of branded pharmaceuticals and other healthcare products, today published its report (reviewed by the auditor) for the first half of the current 2024 financial year and confirmed the preliminary consolidated figures (IFRS).

Grünwald, 14 August 2024 – Dermapharm Holding SE ("Dermapharm"), an innovative and rapidly growing manufacturer of branded pharmaceuticals and other healthcare products, today published its unaudited preliminary consolidated figures (IFRS) for the first half of 2024. Strong growth in the existing business ensures that consolidated revenue remained virtually unchanged in the first six months of financial year 2024 (decline of just 0.6% from EUR 582.1 million in prior-year period to EUR 578.5 million), compensating the effects from the scheduled end of the pandemic phase in vaccine cooperation. Unadjusted EBITDA rose from EUR 137.0 million in the prior-year period to EUR 147.0 million, with the unadjusted EBITDA margin improving by 1.9 percentage points to 25.4% (prior-year period: 23.5%). The adjustments declined significantly by EUR 25.0 million to EUR 6.0 million, with adjusted EBITDA amounting to EUR 153.0 million or 26.4% of net income (prior-year period: EUR 168.0 million or 28.9%).

Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals and other healthcare products, today publishes its results for the first three months of 2024.

Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals, today published its full Annual Report 2023. Dermapharm confirms its preliminary consolidated figures (IFRS) for financial year 2023.

Grünwald, 14 March 2024 – Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals and other healthcare products, today publishes its unaudited preliminary consolidated figures (IFRS) for financial year 2023. The Group increased revenue by 10.8% to EUR 1,135.4 million in the reporting period (prior-year period: EUR 1,024.8 million).

Grünwald, 15 November 2023 – Dermapharm Holding SE ("Dermapharm"), an innovative rapidly growing manufacturer of branded pharmaceuticals and other healthcare products, today publishes its results for the first nine months of 2023.

Dermapharm Holding SE ("Dermapharm"), an innovative and rapidly growing manufacturer of branded pharmaceuticals and other healthcare products, today published its report for the first half of 2023 and confirmed the preliminary consolidated figures (IFRS).

Grünwald, 16 August 2023 – Dermapharm Holding SE ("Dermapharm"), an innovative and rapidly growing manufacturer of branded pharmaceuticals and other healthcare products, today publishes its unaudited preliminary consolidated figures (IFRS) for the first half of 2023. In the first six months of financial year 2023, the Company lifts its revenue by 24% to EUR 582 million (prior-year period: EUR 471 million).

Grünwald, 13 June 2023 – Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals, contractually acquired a significant interest in Pharmazeutische Fabrik Montavit Gesellschaft m.b.H. ("Montavit"), Absam, Tyrol, Austria, via its wholly owned subsidiary Dermapharm AG on 7 June 2023.

Grünwald, 15 May 2023 – Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals, increased its consolidated revenue by 37.8% to EUR 319.1 million in the first quarter of financial year 2023 (previous year: EUR 231.6 million). Adjusted consolidated earnings before interest, taxes, depreciation and amortisation (EBITDA) also rose, climbing by 40.9% to EUR 105.8 million (previous year: EUR 75.1 million).

Grünwald, 28 March 2023 – Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals, today published its full Annual Report 2022. Dermapharm confirms its preliminary consolidated figures (IFRS) for financial year 2022. Despite the difficult macroeconomic environment, Dermapharm succeeded in maintaining its growth trajectory.